sativex

Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical trials. Spasticity is characterized by increased muscle stiffness and spasms, which can be...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported its financial results Tuesday for the first quarter of fiscal 2019. The company reported revenue growth of  67.5 percent. One highlight: the report includes sales of the company's Epidiolex drug, which last year became the first cannabis-based...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported financial results for its fiscal fourth quarter 2018. Compared to analysts' consensus estimates, the company reported a better-than-expected net loss, but its top line missed the expectations. What Happened For the quarter ended Sept. 30, GW...

Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy market and its cannabinoid science platform. The Analyst Leerink's Marc Goodman...

Shares of GW Pharmaceuticals PLC - ADR (NASDAQ: GWPH) soared Wednesday from around $83 per share to close at $104.03 after Reuters reported the company is in talks with an investment banks to consider strategic alternatives. GW Pharmaceuticals is a developer of marijuana-based epilepsy...

There is very limited coverage of marijuana stocks by Wall Street analysts, leading any initiations of coverage to attract quite a bit of attention by the media. Many of the “pot stocks" trade in the “pink” sheets and for good reason. They have disclosed very little information and what they have...